share_log

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Trevi Therapeutics宣佈了5000萬美元的承銷發行定價
Trevi Therapeutics ·  12/16 00:00

NEW HAVEN, Conn., Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share, for total proceeds of $50 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. The offering is expected to close on December 17, 2024, subject to satisfaction of customary closing conditions.

康涅狄格州紐黑文,2024年12月16日 /PRNewswire/ -- Trevi Therapeutics, Inc. (納斯達克: TRVI)是一家臨牀階段生物製藥公司,正在開發用於治療特發性肺纖維化(IPF)和難治性慢性咳嗽(RCC)的研究藥物Haduvio(口服納爾布啡ER)。今天宣佈以每股4.00美元的價格承銷12,500,000股普通股的發行,總收益爲5000萬美元,未扣除承銷折扣和費用以及Trevi應支付的相關費用。此次發行的所有股票均由Trevi出售。預計發行將於2024年12月17日完成,前提是滿足通常的交割條件。

big

The financing includes participation from new and existing investors, including Adage Capital Partners LP, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital Management LP and Vivo Capital.

融資包括新投資者和現有投資者的參與,包括Adage Capital Partners LP、Frazier Life Sciences、Logos Capital、MPm BioImpact、Rubric Capital Management LP和Vivo Capital。

Leerink Partners, Stifel and Oppenheimer & Co. are acting as joint book-running managers for the offering. Needham & Company is acting as lead manager for the offering. Jones and B. Riley Securities are acting as co-managers for the offering.

Leerink Partners、Stifel和Oppenheimer & Co.正在擔任此次發行的聯合簿記管理人。Needham & Company擔任此次發行的首席管理人。Jones 和 b. Riley Securities 正在擔任此次發行的協同管理人。

The shares are being offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-273030), which was filed with the Securities and Exchange Commission (SEC) on June 29, 2023 and declared effective by the SEC on August 15, 2023. This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. The final terms of the offering will be disclosed in a prospectus supplement to be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus may also be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.

這些股票是由Trevi根據於2023年6月29日向證券交易委員會(SEC)提交的S-3表格(檔案號:333-273030)進行的貨架註冊聲明所提供的,該註冊聲明於2023年8月15日獲得SEC的有效承認。本次發行僅通過招股說明書補充和構成註冊聲明的一部分的附帶招股說明書進行。發行的最終條款將通過即將提交SEC的招股說明書補充披露。可用時,招股說明書補充和附帶招股說明書的副本也可以通過以下方式獲得:聯繫:Leerink Partners LLC,聯合部門,53道富銀行,40樓,波士頓,MA 02109,或撥打電話(800)808-7525,分機6105,或通過電子郵件聯繫人syndicate@leerink.com;聯繫:Stifel, Nicolaus & Company, Incorporated,聯合部門,蒙哥馬利街一號,3700室,舊金山,CA 94104,或撥打電話(415)364-2720,或通過電子郵件聯繫人syndprospectus@stifel.com;或聯繫:Oppenheimer & Co. Inc.,聯合招股說明書部門,85百老匯,26樓,紐約,NY 10004,或撥打電話(212)667-8055,或通過電子郵件聯繫人EquityProspectus@opco.com。

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新聞稿不構成出售這些證券的要約,也不構成購買這些證券的要約邀請,亦不應在任何州或管轄區內銷售這些證券,任何此類要約、邀請或銷售在法律上是非法的,需在任何此類州或管轄區的證券法下進行註冊或資格認證後方可進行。

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

關於Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc.是一家臨牀階段的生物製藥公司,正在開發用於治療特發性肺纖維化(IPF)和難治性慢性咳嗽(RCC)患者的研究療法Haduvio(口服納爾布啡緩釋劑)。Haduvio作爲κ受體激動劑和μ受體拮抗劑(KAMA),同時在中樞和外周作用於咳嗽反射弧,這些阿片受體在控制咳嗽過敏反應中發揮重要作用。納爾布啡目前不在美國藥物管理局列管。

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the anticipated closing of the underwritten offering and the expected gross proceeds of the offering, among other things, and other statements containing the words "believes," "anticipates," "plans," "expects," "may," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to market conditions and whether the conditions for the closing of the offering will be satisfied, as well as other risks and uncertainties, as well as other risks and uncertainties set forth in the "Risk Factors" section of Trevi's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC, and in any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.

前瞻性聲明
本新聞稿中關於非歷史事實事項的聲明爲1995年《私人證券訴訟改革法》意義上的「前瞻性聲明」。此類聲明受到風險和不確定性的影響,實際結果可能與此類前瞻性聲明的表達或暗示存在重大差異。此類聲明包括但不限於,關於預計承銷發行的關閉及發行的預期總收益的聲明,此外還有包含「相信」、「預計」、「計劃」、「期望」、「可能」等類似表述的聲明。導致前瞻性聲明不確定性的風險包括:與市場條件相關的不確定性,以及關閉發行的條件是否會滿足的風險,以及在Trevi向SEC提交的截至2024年9月30日季度的10-Q表格的「風險因素」部分中和任何後續提交給SEC的文件中列出的其他風險和不確定性。本新聞稿中包含的所有前瞻性聲明僅在作出聲明的日期有效。Trevi沒有義務更新這些聲明以反映作出聲明後發生的事件或存在的情況,除非法律要求。

Investor Contact
Katie Barrett
Trevi Therapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com

投資者聯繫
凱蒂·巴雷特
Trevi Therapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

媒體聯繫人
羅莎莉亞·斯坎波利
914-815-1465
rscampoli@marketcompr.com

SOURCE Trevi Therapeutics, Inc.

來源 Trevi Therapeutics, Inc.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論